AIMS AND OBJECTIVES: Percutaneous nephrolithotomy (PCNL) remains an effective treatment for large stones. When @entity5274 ( @entity5274 ) is left post operation, antegrade urine flow is often confirmed with antegrade nephrostography (ANG) before tube removal. We compare @entity6693 (MB) test combined with @entity5274 capping trial against ANG to assess antegrade urine flow after PCNL. MATERIALS AND METHODS: One hundred one consecutive @entity1 undergoing PCNL were prospectively enrolled between 7/2014 and 4/2015. An @entity5274 cap was placed the morning of postoperative day 1 (POD1). Failure was defined as need to uncap the @entity5274 for any reason. Two hours after capping, 7cc MB was injected into the @entity5274 . Positive MB test was defined as presence of blue per bladder Foley. ANG was then performed to assess antegrade urine flow. NTs were removed before discharge home when antegrade flow was documented. Primary outcomes included presence of antegrade flow on ANG and @entity5274 removal before discharge home. Receiver operating characteristic (ROC) and areas (Area under the ROC [AUC]), as well as Cohen's kappa coefficient (k), were calculated comparing agreement of capping trial, MB, and ANG with @entity5274 removal. RESULTS: One hundred one subjects were included in this analysis. 52.9% were left-sided surgeries and 60.4% utilized lower pole punctures. On ROC areas evaluating tests for agreement with @entity5274 removal before discharge, MB AUC 0.71 (95% CI 0.60-0.83), capping trial AUC 0.66 (95% CI 0.57-0.75), combed capping trial and MB AUC 0.72 (95% CI 0.61-0.84), and ANG AUC 0.78 (95% CI 0.68-0.88). In predicting @entity5274 removal, ANG performed better than capping trial alone (p   =   0.042), but no differences were seen between MB and ANG (p   =   0.229), combining the capping trial with MB test and ANG (p   =   0.266) or combined testing and MB alone (p   =   0.972). CONCLUSIONS: Combining capping trial with MB injection is similarly accurate for predicting @entity5274 removal after PCNL compared to ANG. Capping trial and MB may be used in combination to obviate the need for ANG.

XXXX Injection as an Alternative to Antegrade Nephrostography to Assess Urinary Obstruction After Percutaneous Nephrolithotomy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5274 :: ('MESH:D005184', 'Disease') :: ['NT', 'nephrostomy tube'] @entity6693 :: ('MESH:D008751', 'Chemical') :: ['methylene blue']
@entity6693 :: (MESH:D008751,Chemical) :: ['Methylene Blue']
